Article: Effects of Nicotinamide Riboside in Duchenne Muscular Dystrophy: Preclinical Findings

PrevNext
Muscle Health Muscular Dystrophy Preclinical

Effects of Nicotinamide Riboside in Duchenne Muscular Dystrophy: Preclinical Findings

Synopsis

Duchenne muscular dystrophy (DMD) causes progressive muscle wasting due to loss of dystrophin. In dystrophin-deficient mice, muscles show depletion of NAD, an important metabolic cofactor. Researchers tested whether supplementing NAD+ with nicotinamide riboside (NR) or inhibiting the NAD-degrading enzyme CD38 could protect muscles. While CD38 inhibition improved some molecular markers, NR had little effect, and neither approach restored muscle strength or prevented damage from repeated muscle stress. This suggests that boosting NAD alone is insufficient to protect muscles in DMD.

Journal

Skeletal Muscle

Share

Read more

Healthy Aging & Longevity

CD38 Deletion and Nicotinamide Riboside Supplementation Slow Axon Degeneration After Facial Nerve Injury: Preclinical Findings

Synopsis After facial nerve injury (axotomy), nerve function often does not fully recover due to axon degeneration, neuron death, and ongoing inflammation. CD38, an enzyme that breaks down NAD+, m...

Read more
Kidney Disease

Nicotinamide Riboside Protects Against Acute Kidney Injury but Not Chronic Kidney Disease: Preclinical Findings

Synopsis Nicotinamide adenine dinucleotide (NAD+) is essential for kidney function, but its production is impaired in acute kidney injury (AKI) and chronic kidney disease (CKD). In human kidney bi...

Read more